Improving treatments for non-alcoholic fatty liver disease
Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis
This study is looking at new medications that could help people with obesity and type 2 diabetes by improving how their bodies handle insulin and sugar, which might also help reduce fat in the liver.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Senseion Therapeutics, INC. NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10461207 on NIH RePORTER |
What this research studies
This research focuses on developing new medications that target a specific ion channel complex, SWELL1, which plays a crucial role in regulating insulin signaling and glucose metabolism. By using a small molecule modulator, researchers aim to enhance the function of SWELL1, potentially improving insulin sensitivity and reducing liver fat accumulation. The approach involves testing these modulators in animal models that mimic human conditions of obesity and type 2 diabetes, which are linked to non-alcoholic steatohepatitis (NASH). If successful, this could lead to new therapies for patients suffering from these metabolic disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with non-alcoholic fatty liver disease, particularly those with obesity or type 2 diabetes.
Not a fit: Patients without non-alcoholic fatty liver disease or those not affected by metabolic syndrome may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with non-alcoholic fatty liver disease and related metabolic conditions.
How similar studies have performed: Other research has shown promise in targeting similar pathways for metabolic diseases, indicating potential for success in this novel approach.
Where this research is happening
Saint Louis, United States
- Senseion Therapeutics, INC. — Saint Louis, United States (Active)
Researchers
- Principal investigator: Lerner, Daniel J — Senseion Therapeutics, INC.
- Study coordinator: Lerner, Daniel J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.